Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720760 | 0.91 | KMT2A (0.61) | KMT2ADPP8DPP7CASP3ANPEP | |
| SCHEMBL23318092 | 0.86 | KMT2A (0.55) | KMT2ACASP3EPHX2TLR2 | |
| SCHEMBL29823463 | 0.83 | KMT2A (0.50) | KMT2ACASP3TLR2 | |
| SCHEMBL17130452 | 0.81 | KMT2A (0.60) | KMT2ACASP3EPHX2 | |
| SCHEMBL178771 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 | |
| SCHEMBL29958970 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 | |
| SCHEMBL29400961 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 | |
| SCHEMBL25358347 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 | |
| SCHEMBL21462054 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 | |
| SCHEMBL29350360 | 0.81 | KMT2A (0.57) | KMT2ATGM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | HANMI FINE CHEMICAL CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | VIP, IAPP, ANPEP | KMT2A 4831/4885DPP8 58/4885DPP7 46/4885 |
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | VIP, PTMS, HM13 | KMT2A 3953/4885DPP8 58/4885DPP7 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.